( very well tolerated in the first dose ...)Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma,Health

very well tolerated in the first dose group. To expedite patient recruitment, Rigel has added additional clinical sites that have significant experience in RA clinical trials. Rigel expects to receive results from the completed clinical trial in the second half of 2007.

Rigel today announced the enrollment of patients in a multi-center, Phase 2 clinical trial to evaluate the safety and efficacy of R788 for the treatment of patients with B-cell lymphoma. Approximately 80% of patients with non- Hodgkin's lymphoma have the B-cell variety, which is characterized by an over- expression of B-cell receptors and the proliferation of B-cells. Research has shown that R788 effectively interrupts the growth of B-cells and signaling proteins that contribute to the survival of these tumors.

The open label clinical trial is expected to enroll a total of approximately 60 patients at 10 major cancer treatment centers in the U.S. and will focus on refractory diffuse large, follicular and mantle B-cell lymphomas. The primary efficacy endpoint will be overall response rate according to standard criteria. Secondary efficacy, safety and pharmacodynamic endpoints, as well as the role of syk activation in predicting responses, will also be measured. Depending on enrollment, results of the clinical trial are expected in 2008.

R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B-cells that promote swelling, inflammatory responses and tissue damage. These activities derive from syk kinase's pivotal role in mediating immunoglobulin signaling inside cells. It is currently being evaluated in two Phase 2 studies with respect to RA and ITP, and enrollment in an additional Phase 2 clinical trial in B-cell lymphoma has commenced. Phase 1 trial results demonstrated that R788 was well tolerated and showed good pharmaceutical properties when administered both alone and, with respect to the treatment of patients with RA, in combinat
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer